CPK20

CPK20 is an experimental **small-molecule potassium channel blocker** reported in preclinical research as a potent inhibitor of **KCNT1** currents, with greater in vitro blocking potency than quinidine in the cited study. It was identified through structure-based screening against a homology model of human KCNT1 and showed selectivity over hERG and Kv7.2 channels, relatively high metabolic stability among the screened compounds, activity against **KCNT2** at lower potency, and the ability to counteract gain-of-function effects of recurrent epilepsy-associated KCNT1 variants including G288S and A934T. Based on the available source, CPK20 appears to be an early discovery-stage candidate being explored for **KCNT1-related developmental and epileptic encephalopathies** and related neurological disorders; no clear developer, manufacturer, clinical formulation, or human development program was identified from the provided evidence.